Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer, Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | January 2004 |
| End Date: | October 2010 |
A Pilot Study of the Safety and Efficacy of Imatinib in Reducing Monocytosis or Leukocytosis in Patients With Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia, Respectively
This study will evaluate the safety and effectiveness of imatinib (Gleevec(Registered
Trademark)) in patients with chronic myelomonocytic leukemia (CMML) and atypical chronic
myelogenous leukemia (CML). These conditions cause uncontrolled growth of malignant
(cancerous) cells in the bone marrow that prevents the bone marrow from functioning normally
in producing blood cells. The cancer cells also can spill over into the blood and invade
other organs of the body. Imatinib has been approved by the Food and Drug Administration for
treating chronic myelogenous leukemia, which has characteristics similar to atypical CML and
to CMML, and data from other research suggests this drug may be able to produce a remission
in forms of leukemia other than CML.
Patients over 18 years of age with atypical CML or CMML may be eligible for this study.
Candidates are screened with a medical history and physical examination, blood tests,
electrocardiogram, chest x-ray, and bone marrow aspiration and biopsy (removal of a small
piece of bone marrow tissue through a needle inserted into the hip bone).
Participants take imatinib capsules once a day for 2 years. If at any time during the study
the patient's blood counts begin to rise, disease symptoms develop, or the disease has
progressed, the dose of imatinib is increased each week until the disease progression is
stopped. Any patient whose disease does not response to treatment after 6 weeks of increased
dosing and 30 days at the maximum daily dose of 800 mg is taken off the study and referred
for different treatment.
Patients are seen by their referring physician every week for the first 4 weeks of the
study, every other week for the next 8 weeks, and then monthly until the study is completed.
At each visit, blood is drawn to monitor for drug side effects and response to therapy. In
addition, patients come to the NIH Clinical Center every 3 months for a complete history and
physical examination and for a bone marrow aspiration and biopsy every 6 months to assess
the effect of treatment on bone marrow cells.
Patients who leave the study before 2 years are followed with laboratory monitoring for 6
months after stopping imatinib; those who remain on the drug for the full 2 years are
monitored for 1 year after stopping the drug.
Trademark)) in patients with chronic myelomonocytic leukemia (CMML) and atypical chronic
myelogenous leukemia (CML). These conditions cause uncontrolled growth of malignant
(cancerous) cells in the bone marrow that prevents the bone marrow from functioning normally
in producing blood cells. The cancer cells also can spill over into the blood and invade
other organs of the body. Imatinib has been approved by the Food and Drug Administration for
treating chronic myelogenous leukemia, which has characteristics similar to atypical CML and
to CMML, and data from other research suggests this drug may be able to produce a remission
in forms of leukemia other than CML.
Patients over 18 years of age with atypical CML or CMML may be eligible for this study.
Candidates are screened with a medical history and physical examination, blood tests,
electrocardiogram, chest x-ray, and bone marrow aspiration and biopsy (removal of a small
piece of bone marrow tissue through a needle inserted into the hip bone).
Participants take imatinib capsules once a day for 2 years. If at any time during the study
the patient's blood counts begin to rise, disease symptoms develop, or the disease has
progressed, the dose of imatinib is increased each week until the disease progression is
stopped. Any patient whose disease does not response to treatment after 6 weeks of increased
dosing and 30 days at the maximum daily dose of 800 mg is taken off the study and referred
for different treatment.
Patients are seen by their referring physician every week for the first 4 weeks of the
study, every other week for the next 8 weeks, and then monthly until the study is completed.
At each visit, blood is drawn to monitor for drug side effects and response to therapy. In
addition, patients come to the NIH Clinical Center every 3 months for a complete history and
physical examination and for a bone marrow aspiration and biopsy every 6 months to assess
the effect of treatment on bone marrow cells.
Patients who leave the study before 2 years are followed with laboratory monitoring for 6
months after stopping imatinib; those who remain on the drug for the full 2 years are
monitored for 1 year after stopping the drug.
The purpose of this study is to evaluate the safety and effectiveness of imatinib for
improving blood counts in patients with chronic myelomonocytic leukemia (CMML) and atypical
chronic myelogenous leukemia (CML).
Although a number of agents have been used to treat these diseases, most patients do not
respond to treatment. Imatinib has been shown in clinical trials to induce high rates of
responses in patients with chronic phase CML. Imatinib has also been shown to be effective
in inducing responses in a subset of patients with CMML and atypical CML and is also
effective in a subset of patients with idiopathic hypereosinophilic syndrome (HES), another
myeloproliferative disorder. Because patients with several different myeloproliferative
diseases have been shown to experience dramatic responses to imatinib, we would like to
determine what proportion of patients with atypical myeloproliferative diseases (CMML and
atypical CML) will respond to this agent.
Prior to enrollment, a thorough clinical evaluation will be performed. A baseline bone
marrow will be obtained to exclude acute leukemia or lymphoma and to assess the degree and
nature of the myeloproliferation. In order to minimize bone marrow suppression, other
myelosuppressive drugs will be tapered and discontinued during the first week of therapy
with imatinib. Complete blood counts will be performed weekly for the first month and every
other week thereafter. Clinical assessments will be performed every three months to assess
for continued response.
improving blood counts in patients with chronic myelomonocytic leukemia (CMML) and atypical
chronic myelogenous leukemia (CML).
Although a number of agents have been used to treat these diseases, most patients do not
respond to treatment. Imatinib has been shown in clinical trials to induce high rates of
responses in patients with chronic phase CML. Imatinib has also been shown to be effective
in inducing responses in a subset of patients with CMML and atypical CML and is also
effective in a subset of patients with idiopathic hypereosinophilic syndrome (HES), another
myeloproliferative disorder. Because patients with several different myeloproliferative
diseases have been shown to experience dramatic responses to imatinib, we would like to
determine what proportion of patients with atypical myeloproliferative diseases (CMML and
atypical CML) will respond to this agent.
Prior to enrollment, a thorough clinical evaluation will be performed. A baseline bone
marrow will be obtained to exclude acute leukemia or lymphoma and to assess the degree and
nature of the myeloproliferation. In order to minimize bone marrow suppression, other
myelosuppressive drugs will be tapered and discontinued during the first week of therapy
with imatinib. Complete blood counts will be performed weekly for the first month and every
other week thereafter. Clinical assessments will be performed every three months to assess
for continued response.
- INCLUSION CRITERIA:
All subjects must be greater than or equal to 18 years of age.
All subjects must meet the established diagnostic criteria for CMML or atypical CML.
The diagnostic criteria for CMML include:
- persistent peripheral blood monocytosis (greater than 1000/mm(3)),
- no Philadelphia chromosome or BCR/ABL fusion gene,
- fewer than 20% blasts in the blood and bone marrow, and
- dysplasia in one or more myeloid lineages. If dysplasia is absent the diagnosis of
CMML can still be made if the other requirements are met and a cytogenetic
abnormality is present in the marrow cells or if monocytosis has been persistent for
at least 3 months and all other causes of monocytosis have been excluded.
OR
The diagnostic criteria for atypical CML include:
- peripheral blood leukocytosis comprised of increased mature and immature neutrophils,
- prominent dysgranulopoiesis,
- no Philadelphia chromosome or BCR/ABL fusion gene,
- neutrophil precursors greater than or equal to 10% of white blood cells,
- basophils less than 2% of white blood cells,
- monocytes less than 10% of white blood cells,
- hypercellular bone marrow with granulocytic proliferation and dysplasia, and fewer
than 20% blasts in the blood and bone marrow.
- Serum creatinine less than 2mg/dl
- ECOG performance status less than 3
- Life expectancy greater than 12 weeks
- All subjects (men and women) must agree to practice abstinence or effective
contraception during administration of imatinib.
- Patients must be able to comprehend the investigational nature of the research and be
willing to sign an informed consent.
EXCLUSION CRITERIA:
Pregnancy or lactation.
HIV positivity or other known immunodeficiency.
Absolute neutrophil count less than 1000/mm(3) or platelet count less than 10,000/mm(3) or
less than 50,000/m(3) with clinical evidence of bleeding.
Infection not adequately responding to appropriate therapy
History of non-hematologic malignancy treated with chemotherapy in past 5 years.
A moribund status or concurrent hepatic, renal, cardiac, metabolic disease of such
severity that death within 12 weeks from initiation of therapy is likely.
Treatment with investigational agent (other than hematopoietic growth factors) within 4
weeks of study entry.
Psychiatric, affective, or other disorder that may compromise the ability to give informed
consent or to cooperate in a research study.
Elevated transaminases (greater than 5 times the upper limit of normal) or elevated
bilirubin (greater than 3 times the upper limit of normal).
Recent exposure to chickenpox or recent history of Herpes zoster (shingles) reactivation.
Imatinib may put patients at increased risk of severe disease.
Left ventricular ejection fraction less than 45%.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
